<h4>Background</h4>Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that has proven efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.